^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | WXSH0011 (FGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical evaluation of WXSH0011, a selective small molecule dual inhibitor of FGFR/c-Met.
Published date:
05/28/2020
Excerpt:
WXSH0011 inhibited cell proliferation in FGFR overexpressed NCl-H1581, SNU-16, RT112/84, Hep3B with IC50 10 nM, 3 nM, 2 nM, 63 nM, c-Met overexpressed MHCC97H and EBC-1 cell line with IC50 0.832 µM, 0.52 µM, FGFR, c-Met dual overexpressed LI-03-0141 (HCC) and ST-02-0063 (Gastric) PDC with IC50 0.19 µM, 0.08 µM....WXSH0011 showed antitumor efficacy in gastric cancer SNU-16 (TGI = 100% @5 mpk, BID), as well as in the liver cancer Hep3B model (TGI = 86.92% @20 mpk, QD).
DOI:
10.1200/JCO.2020.38.15_suppl.e15641
